CN102228536A - 一种治疗糖尿病肾病的中药提取物及其制备方法 - Google Patents
一种治疗糖尿病肾病的中药提取物及其制备方法 Download PDFInfo
- Publication number
- CN102228536A CN102228536A CN2011101544324A CN201110154432A CN102228536A CN 102228536 A CN102228536 A CN 102228536A CN 2011101544324 A CN2011101544324 A CN 2011101544324A CN 201110154432 A CN201110154432 A CN 201110154432A CN 102228536 A CN102228536 A CN 102228536A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- extract
- radix
- diabetic nephropathy
- extracting solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 66
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000012676 herbal extract Substances 0.000 title abstract 4
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 19
- 239000009636 Huang Qi Substances 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims description 75
- 238000011282 treatment Methods 0.000 claims description 64
- 239000000284 extract Substances 0.000 claims description 46
- 239000008187 granular material Substances 0.000 claims description 25
- 238000010992 reflux Methods 0.000 claims description 20
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 19
- 241000600871 Euryale <brittle star> Species 0.000 claims description 18
- 210000000582 semen Anatomy 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229940126678 chinese medicines Drugs 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 235000019202 steviosides Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 23
- 208000024891 symptom Diseases 0.000 abstract description 22
- 102000004169 proteins and genes Human genes 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 230000002485 urinary effect Effects 0.000 abstract description 9
- 102000009027 Albumins Human genes 0.000 abstract description 6
- 108010088751 Albumins Proteins 0.000 abstract description 6
- 230000003907 kidney function Effects 0.000 abstract description 6
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 abstract description 4
- 238000011156 evaluation Methods 0.000 abstract description 4
- 229940080268 lotensin Drugs 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 2
- 239000002245 particle Substances 0.000 abstract 5
- 241000427159 Achyranthes Species 0.000 abstract 1
- 244000268590 Euryale ferox Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 240000004980 Rheum officinale Species 0.000 abstract 1
- 235000008081 Rheum officinale Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 30
- 239000008280 blood Substances 0.000 description 30
- 210000003734 kidney Anatomy 0.000 description 27
- 206010012601 diabetes mellitus Diseases 0.000 description 17
- 230000007812 deficiency Effects 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000029142 excretion Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 229940013618 stevioside Drugs 0.000 description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 2
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 2
- 206010001580 Albuminuria Diseases 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229960003468 gliquidone Drugs 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 235000020905 low-protein-diet Nutrition 0.000 description 2
- 230000029052 metamorphosis Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- -1 absorption carrier Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000032598 susceptibility microvascular complications of diabetes Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 238000009603 uroscopy Methods 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110154432 CN102228536B (zh) | 2011-06-09 | 2011-06-09 | 一种治疗糖尿病肾病的中药提取物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110154432 CN102228536B (zh) | 2011-06-09 | 2011-06-09 | 一种治疗糖尿病肾病的中药提取物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102228536A true CN102228536A (zh) | 2011-11-02 |
CN102228536B CN102228536B (zh) | 2013-03-13 |
Family
ID=44841168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110154432 Active CN102228536B (zh) | 2011-06-09 | 2011-06-09 | 一种治疗糖尿病肾病的中药提取物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102228536B (zh) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102813112A (zh) * | 2012-02-04 | 2012-12-12 | 宁波市鄞州奥胜生物科技有限公司 | 一种用于糖尿病肾病的食品 |
CN103272105A (zh) * | 2013-06-13 | 2013-09-04 | 庞国明 | 一种治疗糖尿病肾病的片剂 |
CN103830380A (zh) * | 2014-03-19 | 2014-06-04 | 首都医科大学 | 一种治疗糖尿病肾病的中药组合物及其制备方法 |
CN104107239A (zh) * | 2014-05-29 | 2014-10-22 | 陈凯 | 一种治疗高血压的中药组合物及其制备方法 |
CN104623587A (zh) * | 2014-12-18 | 2015-05-20 | 青岛市中心医院 | 一种治疗心血管疾病的中药制剂及其制备方法 |
CN104906195A (zh) * | 2015-06-25 | 2015-09-16 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 降低尿蛋白的药物及保健品 |
CN104971102A (zh) * | 2014-04-03 | 2015-10-14 | 成都中医药大学附属医院 | 治疗糖尿病肾病的药物组合物及其制备方法和用途 |
CN105194458A (zh) * | 2015-10-21 | 2015-12-30 | 彭书磊 | 一种治疗糖尿病肾病的中药 |
CN105213716A (zh) * | 2015-10-08 | 2016-01-06 | 刘凯 | 一种治疗糖尿病肾病的中药提取物及其应用 |
CN106389757A (zh) * | 2015-07-29 | 2017-02-15 | 陈明 | 一种治疗糖尿病肾病的药物组合物及其制备方法和用途 |
CN109512875A (zh) * | 2018-12-17 | 2019-03-26 | 北京红太阳药业有限公司 | 一种中药提取物的制备方法及其制备的中药提取物 |
CN109549975A (zh) * | 2018-12-17 | 2019-04-02 | 北京红太阳药业有限公司 | 一种中药提取物的制备方法及其制备的中药提取物 |
CN110755487A (zh) * | 2019-10-08 | 2020-02-07 | 北京汉典制药有限公司 | 一种治疗糖尿病肾病的中药组合物及其制备方法 |
CN112773877A (zh) * | 2021-01-29 | 2021-05-11 | 成都中医药大学附属医院 | 一种治疗糖尿病肾病蛋白尿的药物组合物及其制备方法和用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101041037A (zh) * | 2006-03-22 | 2007-09-26 | 北京市金药源药物研究院 | 一种治疗糖尿病肾病的药物组合及其制备方法 |
-
2011
- 2011-06-09 CN CN 201110154432 patent/CN102228536B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101041037A (zh) * | 2006-03-22 | 2007-09-26 | 北京市金药源药物研究院 | 一种治疗糖尿病肾病的药物组合及其制备方法 |
Non-Patent Citations (2)
Title |
---|
朱云洁,麻金木: "中医药治疗糖尿病肾病的理论及临床研究概述", 《甘肃中医》, vol. 22, no. 11, 30 November 2009 (2009-11-30), pages 6 - 9 * |
黄学民: "止消保肾宁治疗糖尿病肾病肾功能不全(阴阳两虚型)的研究", 《中国优秀硕士学位论文全文数据库》, no. 5, 15 September 2005 (2005-09-15) * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102813112A (zh) * | 2012-02-04 | 2012-12-12 | 宁波市鄞州奥胜生物科技有限公司 | 一种用于糖尿病肾病的食品 |
CN102813112B (zh) * | 2012-02-04 | 2014-07-02 | 宁波市鄞州奥胜生物科技有限公司 | 一种用于糖尿病肾病的食品 |
CN103272105B (zh) * | 2013-06-13 | 2014-11-05 | 庞国明 | 一种治疗糖尿病肾病的片剂 |
CN103272105A (zh) * | 2013-06-13 | 2013-09-04 | 庞国明 | 一种治疗糖尿病肾病的片剂 |
CN103830380B (zh) * | 2014-03-19 | 2015-11-25 | 首都医科大学 | 一种治疗糖尿病肾病的中药组合物及其制备方法 |
CN103830380A (zh) * | 2014-03-19 | 2014-06-04 | 首都医科大学 | 一种治疗糖尿病肾病的中药组合物及其制备方法 |
CN104971102A (zh) * | 2014-04-03 | 2015-10-14 | 成都中医药大学附属医院 | 治疗糖尿病肾病的药物组合物及其制备方法和用途 |
CN104971102B (zh) * | 2014-04-03 | 2018-11-23 | 成都中医药大学附属医院 | 治疗糖尿病肾病的药物组合物及其制备方法和用途 |
CN104107239A (zh) * | 2014-05-29 | 2014-10-22 | 陈凯 | 一种治疗高血压的中药组合物及其制备方法 |
CN104623587A (zh) * | 2014-12-18 | 2015-05-20 | 青岛市中心医院 | 一种治疗心血管疾病的中药制剂及其制备方法 |
CN104906195A (zh) * | 2015-06-25 | 2015-09-16 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 降低尿蛋白的药物及保健品 |
CN104906195B (zh) * | 2015-06-25 | 2019-01-22 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 降低尿蛋白的药物及保健品 |
CN106389757B (zh) * | 2015-07-29 | 2019-08-23 | 陈明 | 一种治疗糖尿病肾病的药物组合物及其制备方法和用途 |
CN106389757A (zh) * | 2015-07-29 | 2017-02-15 | 陈明 | 一种治疗糖尿病肾病的药物组合物及其制备方法和用途 |
CN105213716A (zh) * | 2015-10-08 | 2016-01-06 | 刘凯 | 一种治疗糖尿病肾病的中药提取物及其应用 |
CN105194458A (zh) * | 2015-10-21 | 2015-12-30 | 彭书磊 | 一种治疗糖尿病肾病的中药 |
CN105194458B (zh) * | 2015-10-21 | 2019-12-17 | 薛武 | 一种治疗糖尿病肾病的中药 |
CN109549975A (zh) * | 2018-12-17 | 2019-04-02 | 北京红太阳药业有限公司 | 一种中药提取物的制备方法及其制备的中药提取物 |
CN109512875A (zh) * | 2018-12-17 | 2019-03-26 | 北京红太阳药业有限公司 | 一种中药提取物的制备方法及其制备的中药提取物 |
CN110755487A (zh) * | 2019-10-08 | 2020-02-07 | 北京汉典制药有限公司 | 一种治疗糖尿病肾病的中药组合物及其制备方法 |
CN112773877A (zh) * | 2021-01-29 | 2021-05-11 | 成都中医药大学附属医院 | 一种治疗糖尿病肾病蛋白尿的药物组合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN102228536B (zh) | 2013-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102228536B (zh) | 一种治疗糖尿病肾病的中药提取物及其制备方法 | |
CN102028900A (zh) | 一种治疗代谢综合征的中药及其制备方法 | |
CN104645132B (zh) | 一种治疗糖尿病肾病的中药组合物、制备方法、中药制剂及应用 | |
CN101642529A (zh) | 一种能治疗糖尿病的制剂 | |
CN104815166B (zh) | 一种治疗糖尿病的中药组合物及其制备和应用 | |
CN101513492A (zh) | 一种治疗糖尿病的中药 | |
CN102872334B (zh) | 一种药物组合物在防治糖尿病中的应用 | |
CN102488838B (zh) | 治疗病毒性心肌炎的中药组合物 | |
CN104288594A (zh) | 一种治疗慢性肾脏病气阴两虚证的中药制剂及其制备方法 | |
CN101757523A (zh) | 一种治疗缺铁性贫血的中药 | |
CN104721467B (zh) | 一种治疗糖尿病肾病的中药组合物及其用途 | |
CN103211996B (zh) | 一种治疗糖尿病中药的制备方法 | |
CN103341081B (zh) | 一种治疗高血压并蛋白尿的中药组合物 | |
CN109771578A (zh) | 防治糖尿病及并发症的组合物 | |
CN100528186C (zh) | 一种治疗慢性肾功能衰竭中药复方注射剂的制备工艺以及应用 | |
CN103230552B (zh) | 一种治疗糖尿病的中药 | |
CN102512518B (zh) | 一种治疗糖尿病周围神经病变的中药提取物及其制备方法 | |
CN112451618A (zh) | 一种治疗糖尿病肾病的中药组合物 | |
CN103341082B (zh) | 一种中药组合物在制备治疗高血压并蛋白尿的药物中的应用 | |
CN107823487B (zh) | 一种治疗非酒精性脂肪肝的中药组合物及其制备方法与应用 | |
CN105055967A (zh) | 一种具有辅助降血糖功能的复方保健品及制备方法 | |
CN103989940A (zh) | 一种治疗糖尿病的中药组合物 | |
CN102836358B (zh) | 一种用于治疗糖尿病前期的中药组合物 | |
CN116870095B (zh) | 一种治疗糖尿病的中药组合物 | |
CN115040622B (zh) | 一种用于治疗糖尿病肾病的中药组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160302 Address after: 101599 No. 232 water source road, Miyun Economic Development Zone, Beijing, China Patentee after: Beijing Handian Pharmaceutical Co., Ltd. Address before: The 100069 Beijing Fengtai District right outside the West No. 10 Patentee before: Capital Medical University |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 101599 No. 232 water source road, Miyun Economic Development Zone, Beijing, China Patentee after: Beijing Handian Pharmaceutical Co., Ltd. Address before: 101599 No. 232 water source road, Miyun Economic Development Zone, Beijing, China Patentee before: Beijing Handian Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170929 Address after: 105500 No. 232 water source road, Miyun Economic Development Zone, Beijing, China Co-patentee after: Beijing Red Sun Pharmaceutical Co., Ltd. Patentee after: Beijing Handian Pharmaceutical Co., Ltd. Address before: 101599 No. 232 water source road, Miyun Economic Development Zone, Beijing, China Patentee before: Beijing Handian Pharmaceutical Co., Ltd. |